Capital Fund Management (CFM)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital Fund Management (CFM)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,700	Closed	-$814K	–	2078
2025 Q4	$814K	Sell	13,700 -51,800	-79%	-$2.82M	﹤0.01%	2090
2025 Q3	$3.55M	Sell	65,500 -13,400	-17%	-$766K	0.01%	1452
2025 Q2	$4.34M	Sell	78,900 -10,100	-11%	-$595K	0.01%	1234
2025 Q1	$6.29M	Sell	89,000 -4,900	-5%	-$330K	0.02%	895
2024 Q4	$6.17M	Buy	+93,900	New	+$6.29M	0.02%	981
2021 Q3	–	Sell	-19,000	Closed	-$1.59M	–	1521
2021 Q2	$1.59M	Buy	19,000 +7,500	+65%	+$595K	0.01%	1026
2021 Q1	$868K	Sell	11,500 -16,200	-58%	-$1.32M	0.01%	1003
2020 Q4	$2.43M	Buy	+27,700	New	+$2.2M	0.02%	717
2016 Q2	–	Sell	-6,900	Closed	-$569K	–	1533
2016 Q1	$569K	Buy	+6,900	New	+$561K	0.01%	1087
2015 Q4	–	Sell	-2,000	Closed	-$211K	–	1543
2015 Q3	$211K	Sell	2,000 -3,400	-63%	-$454K	﹤0.01%	1317
2015 Q2	$739K	Buy	+5,400	New	+$669K	0.01%	924
2015 Q1	–	Sell	-3,000	Closed	-$271K	–	1451
2014 Q4	$271K	Sell	3,000 -5,300	-64%	-$441K	﹤0.01%	1383
2014 Q3	$599K	Buy	8,300 +800	+11%	+$52.6K	0.01%	1099
2014 Q2	$467K	Buy	+7,500	New	+$453K	﹤0.01%	1249
2013 Q4	–	Sell	-27,500	Closed	-$1.99M	–	1652
2013 Q3	$1.99M	Sell	27,500 -56,400	-67%	-$3.75M	0.03%	648
2013 Q2	$4.68M	Buy	+83,900	New	+$5.23M	0.07%	371

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Fund Management (CFM)'s BMRN Position: Q1 2026 in Review

Capital Fund Management (CFM) reduced its BioMarin Pharmaceuticals (BMRN) stake by 16% in Q1 2026, selling an estimated $2.06M and leaving 181,065 shares worth $10.2M. The position accounts for 0.05% of the portfolio, ranked #543.

Capital Fund Management (CFM) first reported a position in BMRN in Q2 2013 and has held it in 16 quarters since. The position peaked at $14.4M in Q3 2015. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Capital Fund Management (CFM) held 181,065 shares of BioMarin Pharmaceuticals worth $10.2M as of Q1 2026.
Capital Fund Management (CFM) sold 35,369 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $2.06M.
BioMarin Pharmaceuticals made up 0.05% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #543 holding.
Capital Fund Management (CFM) first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
Capital Fund Management (CFM)'s BioMarin Pharmaceuticals position peaked at $14.4M in Q3 2015.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.